David A. Siegel Arbutus Biopharma Corp Call Options Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ABUS
# of Institutions
156Shares Held
99.6MCall Options Held
2.31MPut Options Held
525K-
Morgan Stanley New York, NY21.7MShares$75.8 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY12.9MShares$44.9 Million26.34% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$40.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$31.1 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY8.39MShares$29.3 Million10.86% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $523M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...